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The Notch signaling pathway preservation across species hints to the indispensable role it plays during evolution. Over the last
decade the science community has extensively studied the Notch signaling pathway, with Notch emerging as a key player in
embryogenesis, tissue homeostasis, angiogenesis, and immunoregulation. Multiple sclerosis (MS) is an incurable yet treatable
autoimmune chronic inflammatory disease of the central nervous system. The aim of this review is to provide a brief description
of the Notch signaling pathway, and summarize the current literature implicating Notch in the pathogenesis of MS.
1. Introduction
The evolutionary conserved Notch signaling pathway is a
c r u c i a lp l a y e ri nc e l lf a t ed e c i s i o nf r o me m b r y o g e n e s i st o
a d ul tl i f ea n dp l a y sak eyr o l ei nab r oa dr a n g eo fc e ll ul a rp r o -
cesses including activation, proliferation, differentiation, and
apoptosis.Notchsignalingorchestratesnormalcellandtissue
development and has been implicated in the pathogenesis of
some of the most challenging medical problems facing our
society. In this review, we are going to focus on the influence
of this pathway on autoimmune diseases.
The canonical Notch signaling cascade is initiated when
a Notch receptor engages a Notch ligand expressed on a
neighboring cell. This triggers a series of enzymatic reactions
leading to the release of the Notch receptor intracellular
domain, which translocates to the nucleus and forms an
active transcription complex regulating target genes expres-
sion [1–3].
Multiple sclerosis (MS) is a chronic, often disabling
autoimmune inflammatory demyelinating disease of the
central nervous system (CNS) affecting mostly the young
adultpopulation.Unknownenvironmentalfactorsstillunder
investigation are thought to trigger MS in genetically pre-
disposed individuals. T-helper (Th) cells, so called for their
ability to coordinate and fine-tune the immune response,
initiate an attack against “self” antigens expressed mainly on
oligodendrocytes (OLs) leading to chronic inflammation[4].
Notch signaling has been shown to regulate the development
and function of both Th cells and OLs, with several groups
reporting on the potential therapeutic implications of Notch
pathway targeting in MS.
2. Notch Signaling
In 1914, John S. Dexter described a heritable “beaded” wing
phenotype in the fruit fly Drosophila melanogaster.T w e l v e
yearslater,ThomasH.MorganpublishedhisworkTheTheory
of the Gene in which he identified multiple mutant alleles
resulting in this heritable “notched” wings phenotype. The
gene was therefore appropriately called Notch.Th eN o t c h
signaling pathway is now recognized as a cornerstone of cell-
to-cell communication.
In humans, the classic Notch signaling pathway consists
of four heterodimeric transmembrane receptors (Notch 1,
2, 3, and 4) and their ligands (Delta-like 1, 3, and 4 and
Jagged 1 and 2) [1]. The Notch receptor engagement by
its ligand expressed on an adjacent cell is followed by
two consecutive proteolytic reactions mediated by ADAM
metalloproteases and the Presenilin family of 𝗾-secretases.
These enzymatic reactions lead to the cleavage of the recep-
tor in its transcellular domain region, releasing the Notch
intracellular domain (NICD) which then translocates to the
nucleus. Once in the nucleus, NICD forms a transcriptional
complex with the recombination signal binding protein for
immunoglobulinkappaJregion(RBP-J𝜅)andthecoactivator
mastermind-like (MAML) proteins, thus converting RBP-J𝜅2 Clinical and Developmental Immunology
Dendritic cell
ADAM protease
𝗾-Secretase
1
,
3
,
 
a
n
d
 
4
D
e
l
t
a
J
a
g
g
e
d
1
,
2
Cytoplasm
CD4+
Nucleus
NICD
NICD
Target gene
N
o
t
c
h
M
A
M
L
RBP-J𝜅
Figure 1: Schematic illustration of Notch signaling pathway. Bind-
ing of the extracellular part of Notch receptor to ligands of the
Delta and Jagged families induces proteolytic cleavage of Notch,
releasing the intracellular part of the protein (NICD). NICD is then
translocated to the nucleus and binds to the nuclear transcription
factor RBP-J𝜅 inducing its conversion from a repressor into an
activator to stimulate the transcription of Notch target genes.
from a transcriptional repressor to a transcriptional activa-
tor. The NICD/RBP-J𝜅/MAML complex then modulates the
expression of their target genes [2, 3]( Figure 1).
3. T-Helper Cell Differentiation
Three signals are required for efficient T cell differentiation.
The first is in the form of antigen presented by an antigen-
presenting cell (APC), such as a dendritic cell (DC). The
second signal comes in the form of costimulatory receptors
on T cells engaging their cognate ligands on APCs. Small
signaling protein molecules, that is, cytokines, provide the
third signal [5]. Albeit an oversimplification, Notch signaling
falls under the third signal category and fine-tunes the T cell
response [6].
Todate,numerousT-helpercellsubsetshavebeendefined
mainly based on the expression of master transcriptional
regulators and cytokine production profiles (Figure 2)[ 7].
Antigen presentation in the presence of IL-12 induces the
expression of T-bet and production of IFN-𝗾, therefore
promoting na¨ ıve T cell polarization into the Th1 phenotype.
IL-4 induces GATA3 expression and IL-4 production and is
necessary for Th2 cell polarization. IL-6 and TGF-𝗽 induce
ROR𝗾t expression and IL-17 production in Th17 cells. TGF-
𝗽 is necessary for foxp3 expression and regulatory T cell
(Treg) differentiation. The IL-9 producing Th (Th9) cells
require both IL-4 and TGF-𝗽, which induce IRF4 and PU.1
expression, respectively [7].
While Th cell subsets are necessary for providing immu-
nity against infectious pathogens, their aberrant response is
to blame in several medical problems such as autoimmune
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Figure 2: Schematic illustration of CD4
+ T cell differentiation
into effector or regulatory T cells. Depending on the cytokine
milieu (shown above the arrows) present at the time of the initial
engagement of their TCR, naive CD4
+ T cells can differentiate
into various subsets of T-helper cells (Th1, Th2, Th9, and Th17).
H o w e v e r ,i nt h ep r e s e n c eo fT G F - 𝗽1, naive T cells convert into
foxp3-expressing induced Treg (iTreg) cells. For each T-helper cell
differentiationprogram,specifictranscriptionfactors(shownbelow
thearrows)havebeenidentifiedasmasterregulators(T-bet,GATA3
and ROR𝗾t) for Th1, Th2, and Th17, respectively. IRF4, PU.1, and
RBP-J𝜅transcriptionfactorshavebeenshownrecentlytocontribute
to the induction to Th9 cells.
diseases,allergies,andmalignancies.Therefore,aThcelltype
could be either “good” or “bad” depending on the immuno-
logicalcontext.Studiesinhumansaswellasinanimalmodels
of MS suggest that Th1 and Th17 cells are mostly pathogenic,
while Th2 and Treg cells are anti-inflammatory. The role of
Th9 cells in autoimmune diseases is still controversial as they
might be a plastic, nonterminally differentiated phenotype
[8].
4. Delta-Like Ligands and Th Subsets
Several in vitro studies support a role for Delta-like ligands
(Dll) in promoting Th1 cell differentiation [9–11]. Briefly,
APCs expressing Dll promote Th1 while suppressing Th2
cell differentiation. Concurrently, exogenous stimuli that
would enhance APCs polarizing potential of Th1 cells also
increase the APCs expression of Dll [9]. RBP-J𝜅 and NICD
were reported to bind to the Tbx21 and Ifng promoters,
respectively, two hallmarks of Th1 cells [10, 11].
With regard to Th17 cells, Mukerjee et al. show that
under Th17 polarizing conditions rDll4 treatment signifi-
cantly enhances IL-17 production while 𝗾-secretase inhibitor
(GSI) mediated inhibition of Notch signaling abrogates it.
Furthermore, RBP-J𝜅 was found to bind to the Il17 promoter
and this was reduced in the presence of GSI [12].
Bassil et al. show that Dll4 mediated signaling inhibits
TGF-𝗽-induced Treg development as well as Janus kinase
3-induced STAT5 phosphorylation, a transcription factorClinical and Developmental Immunology 3
k n o w nt op l a yak e yr o l ei nF o x p 3e x p r e s s i o na n dm a i n -
tenance [13]. The role of Dll4 in Treg development was
f u r t h e rc o n fi r m e db yB i l l i a r de ta l .b ys h o w i n gt h a ta n t i -
Dll4 Ab treatment converts early T cell progenitors to
immature tolerogenic DCs that promote Treg-cell expansion
[14]. Adding another dimension to the picture, Hue et al.
demonstrate that pretreatment with Notch ligands Dll4 and
Jagged1 sensitizes CD4
+CD25
− effector T cells to Treg-cell
mediated suppression through increased TGF-𝗽RII expres-
sion and Smad3 phosphorylation [15].
5. Jagged Ligands and Th Subsets
What applies to the Dll and Th1/Th2 cells is almost opposite
tothefindingsseenwiththeJaggedligands.APCsexpressing
Jagged ligands promote Th2 cells while suppressing Th1 cell
differentiation. Concurrently, pathogens that enhance APCs
polarizing potential for Th2 cells also increase the APCs
e x p r e s s i o no fJ a g g e dl i g a n d s[ 9]. Furthermore, Notch and
RBP-J𝜅 were found to bind the Gata3 promoter and the
HS5 site of the IL4 enhancer, both critical genes in Th2 cell
differentiation [9, 16, 17].
Jagged ligands are thought to enhance the development
and function of regulatory T cells. In a human in vitro study,
Vigourouxetal.reportontheinductionofanantigenspecific
IL-10 producing regulatory T cell population (Tr1) following
stimulation by Jagged1 transduced B cells [18]. Kared et al.
show that a population of hematopoietic progenitor cells
(HPCs) highly expressing Jagged2 ligand activated Notch3
signaling in Treg cells enhancing their expansion and sup-
pressivefunction.Thissignalingmechanismrequiredcell-to-
cell interaction and was inhibited by GSI [19].
Asano et al. have demonstrated that Treg suppressor
cells express Jagged1 while the responder cells (CD4
+CD25
−)
express Notch1. Anti-Notch1 and to a lesser extent anti-
Jagged1 Abs inhibited the suppressive function of Treg cells.
Furthermore, they show that Jagged1-mediated Notch1 acti-
vation enhances TGF-𝗽-induced Smad3 transcription and
translocation to the nucleus, a key component of TGF-𝗽
mediated signaling [20].
With regard to Th9 cells, Elyaman et al. have found
Notch1 and Notch2 conditional ablation to significantly
reduce IL-9 production. In fact, Jagged2 mediated Notch
signaling promotes RBP-J𝜅/NICD1/Smad3 transcriptional
complexformationandbindingandtransactivationoftheIl9
promoter [21].
6. Notch Intracellular Domain and
Noncanonical Signaling in Th Subsets
In addition to the data that has been generated involving
the Delta-like and Jagged ligands, a plurality of data has
been generated without regard to ligand to show Notch
involvement in T-helper subset differentiation, and more
workwillneedtobedonetofullyelucidatethespecificligand
pathway.
RBP-J𝜅 a n dN I C Dh a v eb e e ns h o w nt ob i n dt h eG a t a 3
promoter, without specific ligand activation [16, 17]. Similar
r e s u l t sh a v eb e e ns h o w nf o rt h eT b x 2 1a n dI f n gp r o m o t e r sa s
well[8,9].Thusthespecificligandpathwayofmanyaspectsof
Notch signaling remains to be determined despite consistent
results showing involvement in Th development.
Another topic of active research is the role of non-
canonicalNotchsignalinginThdifferentiation.Perumalsamy
et al. found that NICD in the plasma membrane, rather
than the nucleus, was associated with improved survival
of Tregs [22]. Additionally Auderset et al. showed Notch
signaling independent of RBP-J𝜅 to be important for Th1
development during parasitic infections [23]. The increasing
bodyofevidencepointstoasignificantrolefornoncanonical
Notch signaling in the differentiation and proliferation of Th
subsets (see Table 1), and this will likely be an active area of
research in the future.
7. Notch and Oligodendrocytes
Oligodendrocyte (OL) projections provide neurons with a
protective and insulating myelin sheath, which optimizes
nerve conduction speeds. The autoimmune response target-
ing this myelin sheath results in slowing nerve conduction
velocities and is responsible for the neurological deficits
in MS. Therefore, immunoregulatory approaches targeting
oligodendrocyte progenitor cell (OPC) proliferation and
differentiation would be invaluable. It is worth noting that
several groups have demonstrated that the timing of Notch
signaling differentially regulates OPC development, with
Dll1- and Jagged1-mediated signaling inhibiting OPC matu-
ration while enhancing their expansion [24–26].
8. Notch and Animal Models of MS
Experimental autoimmune encephalomyelitis (EAE), the
most widely used model for MS [27, 28], is induced by active
immunization of mice with myelin antigens emulsified in
adjuvant [29]. Alternatively, EAE can be induced by passive
transfer of activated myelin-specific cellular clones or cell
lines[30].Theiler’smurineencephalomyelitisvirus-(TMEV-)
induced demyelinating disease (TMEV-IDD), another popu-
lar model for MS, is induced by intracerebral injection with
TMEV resulting in CNS inflammation [28].
Minter et al. nonspecifically inhibited Notch signaling
by oral or intraperitoneal administration of GSI in the
PLP/SJL EAE model. This resulted in a significant decrease
in clinical disease and Th1 associated cytokines reduction
[10]. Keerthivasan et al. followed up on this work by showing
that Notch plays a role in Th17 differentiation and GSI in the
PLP/SJL EAE model reduces IL-17 production [31].
Jurynczyk et al. provided compelling evidence that
Notch3 may play a significant role in EAE when they showed
that, by using GSI against specific Notch3 and not Notch1,
there is a significant decrease in clinical disease score as well
asTh1andTh17cytokinesusingthePLP/SJLEAEmodel[32].
Among all Notch ligands, the role of Dll4 in animal
models of MS has been the most studied role. In 2010,
Takeichi et al. showed that Dll4 expression is significantly
upregulatedonDCsintheTMEV-IDDmodel.Dll4blockade4 Clinical and Developmental Immunology
T a b l e1 :N o t c ha n dThs u b s e t s .
Ligand/pathway Method Results References
Dll BMDC LPS stimulation ↑Dll4 mRNA A m s e ne ta l . ,2 0 0 4[ 9]
Dll Dll1 expressing APC/CD4
+ Tc e l l s
coculture ↑IFN-g
Dll CD8
− DCs LPS stimulation ↑Dll4 expression Skokos and Nussenzweig,
2007 [33] Dll Dll4-mFc CD4
+ Tc e l lt r e a t m e n t ↑IFN-g
Dll DCs TLR2/TLR9 ligation ↑DCs Dll expression, ↑T-bet, ↑IFN-g, and
↓IL-4 by CD4
+ Tc e l l
Sun et al., 2008 [34]
Dll CD4
+ T cell recDll4 treatment ↑RORc activation, ↑IL-17 Mukherjee et al., 2009 [12]
Dll CD4
+ T cell recDll4 treatment ↓phospho-Jak3, ↓phospho-Stat5, and
↓Foxp3 Bassil et al., 2011 [13]
Dll CD4
+ CD25
− cells Dll4 and Jagged1
pretreatment ↑TGF-𝗽RII and phospho-Smad3 Hue et al., 2012 [15]
Jagged Jagged1 transduction of human APCs Induction of IL-10 producing Tr1 cells Vigouroux et al., 2003 [18]
Jagged HPCs expressing Jagged2 ↑Treg expansion and function Kared et al., 2006 [19]
Jagged Notch1 or Jagged1 blockade ↓T r e gf u n c t i o n A s a n oe ta l . ,2 0 0 8[ 20]
Jagged BMDC LPS stimulation ↑Jagged1 mRNA
A m s e ne ta l . ,2 0 0 4[ 9]
Jagged Jagged1 expressing APCs/CD4
+ Tc e l l s
coculture ↑IL-4, ↑IL-5
NICD NICD forced expression in CD4
+ Tc e l l s N I C Dr e g u l a t e sIL4 transcription
NICD RBP-J𝜅/NICD1/Smad3 forced expression
in CD4
+ Tc e l l s
RBP-J𝜅/NICD1/Smad3 complex binds
and transactivates Il9 promoter Elyaman et al., 2012 [21]
NICD Cell line transduction RBP-J𝜅 binds Tbx21 promoter Minter et al., 2005 [10]
NICD Splenocytes aCD3/aCD28 stimulation NICD binds Ifng promoter Shin et al., 2006 [11]
NICD NICD forced expression in CD4
+ T cells NICD binds the Gata3 promoter Fang et al., 2007 [17]
NICD Notch1 blockade in Th17 cells ↓Th17 associated cytokines Keerthivasan et al., 2011 [31]
NICD Cell line transfection RBP-J𝜅 binds the Gata3 promoter Amsen et al., 2007 [16]
Noncanonical In vivo notch ablation in CD4
+ cells Notch1 and Notch2 redundantly essential
for Th1 development Auderset et al., 2012 [23]
Noncanonical Mutant NICD in Notch1 KO Tregs NICD targeting plasma membrane
improves Treg survival P e r u m a l s a m ye ta l . ,2 0 1 2[ 22]
Table 2: Notch and animal models of MS.
MS animal model Method Results References
EAE (PLP/SJL) GSI ↓Disease, ↓Th1 Minter et al., 2005 [10]
EAE (PLP/SJL) Anti-Notch3 ↓Disease, ↓Th1, and ↓Th17 Jurynczyk et al., 2008 [32]
EAE (PLP/SJL) GSI ↓Disease, ↓Th17 Keerthivasan et al., 2011 [31]
EAE (MOG/B6) Anti-Dll1 ↓Disease, ↓Th1 Elyaman et al., 2007 [35]
TMEV-IDD Anti-Dll1 ↓Disease, ↓IFN-𝗾,a n d↓IL-4 Tsugane et al., 2012 [36]
TMEV-IDD Anti-Dll4 ↓Disease, ↓IFN-𝗾,a n d↓IL-17 Takeichi et al., 2010 [37]
EAE (PLP/SJL) Anti-Dll4 ↓Disease, ↓Th1, and ↓Th17 Reynolds et al., 2011 [38]
EAE (MOG/B6) Anti-Dll4 ↓Disease, ↓Th1, ↓Th17, ↑Th2, and ↑Treg Bassil et al., 2011 [13]
EAE (MOG/B6) Anti-Jagged1 ↑Disease, ↓IL-10 Elyaman et al., 2007 [35]
EAE (MOG/B6) Jagged1 peptide ↓Disease, ↓IFN-𝗾,a n d↑IL-4 Palacios et al., 2007 [39]
EAE (MOG/B6)
Anti-Jagged2 signaling molecules prior to
immunization
↓Disease, ↑Treg
Elyaman et al., 2012 [21]
Anti-Jagged2 signaling molecules at time
of immunization
↑Disease, ↑IL-17Clinical and Developmental Immunology 5
Table 3: Notch and animal models of immune mediated diseases.
Animal model Method Results References
Allergic conjunctivitis Anti-Dll4 ↑Disease, ↑Th2 Fukushima et al., 2008 [40]
Allergic asthma Anti-Dll4 ↑Disease, ↓Treg function Huang et al., 2009 [41]
Allergic airway response Anti-Dll4 ↑Disease, ↑Th2 Jang et al., 2010 [42]
Autoimmune uveoretinitis Anti-Dll4 ↑Disease, ↓Th17 Ishida et al., 2011 [43]
T1D Anti-Dll4 ↓Disease, ↑Treg Billiard et al., 2012 [14]
Graft versus host disease Anti-Dll4 ↑Survival, ↓Th1, and ↓Th17 Mochizuki et al., 2013 [44]
Allogeneic cardiac transplant Anti-Dll1 ↑Survival, ↓Th1, and ↓cytotoxic T cell Riella et al., 2011 [45]
Airway hyperresponsiveness Jagged1-Fc ↑Disease, ↑Th 2 O k a m o t oe ta l . ,2 0 0 9[ 46]
Murine cardiac transplant Anti-Jagged2 signaling Ab ↓Survival, ↑IL-2, and ↑IL-6 Riella et al., 2013 [47]
significantly ameliorated the clinical course of the disease,
which was attributed to a decrease in mononuclear cell
infiltration of the target tissues and reduction in IFN-𝗾 and
IL-17 production [37].
In 2011, in concordance with the TMEV-IDD study,
Reynolds et al. described an increase in Dll4 expression
o nA P C si nt h eP L P / S J LE A Em o d e l ,w i t hD l l 4b l o c k a d e
alleviating clinical disease and decreasing IFN-𝗾 and IL-17
producing CD4
+ T cells frequency and leukocyte infiltration
of the CNS, while having no effect on the Foxp3 mRNA
expressionlevels.Reynoldsetal.attributetheeffectsobserved
with Dll4 blockade to a downregulation of the chemokine
receptors CCR2 and CCR6 expression on CD4
+ Tc e l l s ,
leading to their differential migration and accumulation in
the CNS [38]. Also in 2011 and in agreement with the
previous studies, Bassil et al. showed that Dll4 blockade in
the MOG/B6 EAE model alleviates the clinical EAE severity
a n ds h i ft st h ei m m u n eb a l a n c ef r o maTh 1 / Th 1 7m e d i a t e d
response toward a Th2/Treg mediated response. In this study,
the effects were mainly attributed to the role Dll4 plays in
regulating Treg development, with Treg depletion prior to
EAEinductionabrogatingtheanti-Dll4mAbprotectiveeffect
[13].
Dll1 contribution to the EAE model has been described
by Elyaman et al. in 2007, showing DC upregulation of
Dll1 expression during the induction phase of the disease.
Dll1 blockade reduced the disease severity and CD4
+IFN-
𝗾
+ cell frequency, while Dll1 ligation had the opposite effect.
M o d u l a t i o no ft h eD l l 1m e d i a t e ds i g n a l i n gh a dn oe ff e c to n
CD4
+Foxp3
+ cell frequencies [35]. Tsugane et al. reportedon
Dll1 blockade in the TMEV-IDD model in 2012. A decrease
in IFN-𝗾, IL-4, and IL-10 producing CD4
+ Tc e l l sa n da n
increase in IL-17 producing CD4
+Tc e l l sw e r eo b s e r v e di n
the spinal cords of treated mice. This resulted in a significant
suppression of the disease both clinically and histologically
[36].
The role of the Jagged ligands in animal models of MS
h a sn o tb e e ns t u d i e da sm u c ha st h e i rD l lc o u n t e r p a r t s .O u r
grouphasshownthattheadministrationofanti-Jagged1mAb
exacerbated EAE clinical disease and was associated with
a decrease in IL-10-producing CD4
+ Tc e l l si nt h eC N S .
In contrast, the administration of Jagged1-Fc protected the
mice from disease and increased the frequency of IL-10-
producing CD4
+ Tc e l l s[ 35]. Using a human Jagged1 agonist
peptide, Palacios et al. have also concluded that Jagged1
signaling ameliorates EAE course, which was associated
with an increase in CD25
+Foxp3
+ Tc e l lf r e q u e n c y[ 39].
In a recent study, Elyaman et al. reported that the timing
of Jagged2 mediated signaling differentially regulates EAE.
In that report, we show that Notch signaling is required
for optimal IL-9 production. Jagged2 signaling molecule
administration before antigen immunization promotes IL-
9-mediated Treg-cell expansion and suppresses EAE, while
Jagged2 signaling molecule administration concurrent with
immunization worsens EAE, with IL-9 favoring Th17 cell
expansioninthisinflammatorymilieu[21].TheroleofNotch
s i g n a l i n gi na n i m a lm o d e l so fM Si ss u m m a r i z e di nTable 2.
Notch signaling has been investigated in other models
of immune mediated diseases and the data complements the
findingsintheEAEsystem.Notsurprisingly,theeffectonthe
clinical disease was largely dependent on the immunological
context. The data is summarized in Table 3.
9. Notch and MS
Despite the overwhelming evidence supporting the role of
Notch signaling in Th cell development and in regulating
the outcome in animal models of MS, studies in the human
system remain scarce and mostly point to Jagged1 or were
ligand independent.
Zhang et al. studied chronic active MS lesions and
concluded that the expression of Jagged1 in remyelinated
M Sl e s i o n si sn o n s i g n i fi c a n t .O nt h eo t h e rh a n d ,i na c t i v e
MSlesionslackingremyelination,Jagged1ishighlyexpressed
by hypertrophic astrocytes, with Notch1 being preferentially
expressedinnondifferentiatedOLs[26].Inastudyofchronic
silent MS lesions, Nakahara et al. observed a high level
of activation of Notch1 through the noncanonical Notch
signaling pathway, while the classic Notch signaling pathway
is inhibited [48].
An analysis of gene networks regulating T cell activa-
tion in MS patients by Palacios et al. has concluded that
Jagged1 is consistently modified in the disease state making
it a potential therapeutic target in MS [39]. However, the
strongest inculpating evidence emerged in 2006 when a
meta-analysis of the Genetic Analysis of Multiple Sclerosis
in EuropeanS (GAMES) project involving 13,896 individuals
identified Jagged1 as a susceptibility gene for MS [49].6 Clinical and Developmental Immunology
These observations taken together with the data from
in vitro studies further highlight the key role of the Notch
signaling pathway in regulating the immune balance in MS.
10. Concluding Remarks
The scientific community has provided overwhelming evi-
dence implicating the Notch signaling pathway in the
pathogenesis of autoimmune diseases including MS. Notch-
mediatedsignalingemergesasakeyregulatorofthedevelop-
ment of Th cell subsets promoting autoimmunity, as well as
other Th subsets playing an anti-inflammatory role [4, 10, 13,
21, 35] .Th i sd i c h o t o m yh a sa l s ob e e nd e m o n s t r a t e di nO P C s
where the nature and timing of Notch signaling could either
enhance or inhibit OPC maturation and expansion [25, 26].
Therefore, Notch signaling regulates the development and
function of pathogenic cells as well as cells with regener-
ative and anti-inflammatory properties. This makes Notch
signaling targeted immunotherapy extremely promising yet
problematic for the same reason. To complicate the picture,
w h i l ei ts e e m sl i k e l yt h a tThs u b s e t sa r eav a l i dt a r g e tf o r
Notch immunotherapy, APCs and other myeloid cells clearly
p l a yar o l ei nE A Ea n ds h o u l dn o tb ee x c l u d e da sp o t e n t i a l
cell-specific targets.
Theobviouschallengesarisefromthedifficultiesindeliv-
ering the right immunomodulatory signal to the right target
cellattherighttime.Tofurthercomplicatethepicture,Notch
receptors and ligands are ubiquitously expressed making the
nonselective approach less than ideal. We believe that the
current literature supports and encourages a Notch signaling
targeted immunotherapy even in a noncell-specific targeting
system through the use of signaling pathway inhibitors such
as GSI or the use of mAbs and signaling molecules. However,
harnessing the immense therapeutic potential of the Notch
signaling pathway modulation lies in taking advantage of
future advances and breakthroughs in cell-specific targeted
drug delivery systems.
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